Outcomes Following Delta Xtend Reverse Shoulder System

Reverse Total Shoulder Arthroplasty Clinical Trial

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02014350
• Other study ID #: RI2013
• Status: Enrolling by invitation
• Phase: N/A
• First received: December 12, 2013
• Last updated: December 17, 2013

Study information

• Verified date: December 2013
• Source: Rothman Institute Orthopaedics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

To collect medium to long-term survivorship implant outcomes on the DePuy Delta Xtend Reverse Shoulder Stystem.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 0
• Est. primary completion date: March 2020
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients whom were implanted with the DePuy Delta Xtend Reverse Total Shoulder System in the time frame indicated. Patients must be willing to sign the consent form and complete all follow-up visits.

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Reverse Total Shoulder Arthroplasty

Intervention

Device:
• DePuy Delta Xtend Reverse TSA

Locations

Country	Name	City	State
United States	Rothman Institute	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Rothman Institute Orthopaedics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Implant Survivorship		10 years post-operative	Yes